{
  "symbol": "MRK",
  "year": 2023,
  "Period": "Q3",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.2135,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.106
  },
  "top_positive": [
    {
      "sent": "Unregistered Sales of Equity Securities and Use of Proceeds Issuer purchases of equity securities for the three months ended March\u00a031, 2023 were as follows: ISSUER PURCHASES OF EQUITY SECURITIES ($\u00a0in\u00a0millions) Period Total\u00a0Number of Shares Purchased (1) Average\u00a0Price Paid Per Share Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs Approximate\u00a0Dollar\u00a0Value\u00a0of\u00a0Shares That May Yet Be Purchased Under the Plans or Programs (1) January 1 - January 31 \u2014 \u2014 \u2014 $5,047 February 1 - February 28 328,800 $108.43 328,800 $5,012 March 1 - March 31 1,066,937 $106.55 1,066,937 $4,898 Total 1,395,737 $107.00 1,395,737 (1) Shares purchased during the period were made as part of a plan approved by the Board of Directors in October 2018 to purchase up to $10 billion of Merck\u2019s common stock for its treasury.",
      "score": 0.968
    },
    {
      "sent": "These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development.",
      "score": 0.9451
    },
    {
      "sent": "These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development.",
      "score": 0.9451
    }
  ],
  "top_negative": [
    {
      "sent": "- 36 - Phase 2 Cancer MK-0482 (2) Non-Small-Cell Lung MK-1308 (quavonlimab) (2) Non-Small-Cell Lung MK-1308A (quavonlimab+pembrolizumab) Colorectal Hepatocellular Melanoma Small-Cell Lung MK-2140 (zilovertamab vedotin) Bladder Breast Gastric Hematological Malignancies Non-Small-Cell Lung Ovarian Pancreatic MK-2870 (1)(3) Neoplasm Malignant MK-3475 Keytruda Advanced Solid Tumors Prostate MK-3543 (bomedemstat) Myeloproliferative Disorders MK-4280 (favezelimab) (2) Non-Small-Cell Lung MK-4280A (favezelimab+pembrolizumab) Baldder Esophageal Melanoma Renal Cell Small-Cell Lung MK-4830 (2) Colorectal Esophageal Melanoma Non-Small-Cell Lung Ovarian Renal Cell Small-Cell Lung MK-5684 (1) Prostate MK-5890 (boserolimab) (2) Non-Small-Cell Lung Small-Cell Lung Cancer MK-6440 (ladiratuzumab vedotin) (1)(3) Breast Esophageal Gastric Head and Neck Melanoma Non-Small-Cell Lung Prostate Small-Cell Lung MK-6482 Welireg (3) Biliary Colorectal Endometrial Esophageal Hepatocellular Pancreatic Rare cancers Von Hippel-Lindau Disease-Associated Tumors (EU) MK-7119 Tukysa (1) Advanced Solid Tumors Biliary Bladder Cervical Endometrial Gastric Non-Small-Cell Lung MK-7339 Lynparza (1)(3) Advanced Solid Tumors MK-7684A (vibostolimab+pembrolizumab) Biliary Bladder Breast Cervical Colorectal Endometrial Esophageal Gastric Head and Neck Hematological Malignancies Hepatocellular Ovarian Prostate Cancer MK-7902 Lenvima (1)(2) Biliary Melanoma Pancreatic Prostate Small-Cell Lung V940 (1)(2) Melanoma Dengue Fever Virus Vaccine V181 HIV-1 Infection MK-8591B (islatravir+MK-8507) (4) MK-8591D (islatravir+lenacapavir) (1)(5) Hypercholesterolemia MK-0616 Nonalcoholic Steatohepatitis (NASH) MK-6024 (efinopegdutide) Pulmonary Arterial Hypertension MK-5475 Pulmonary Hypertension Due To Left Heart Disease MK-7962 (sotatercept) Schizophrenia MK-8189 (6) Thrombosis MK-2060 Treatment Resistant Depression MK-1942 - 37 - Phase 3 (Phase 3 entry date) Under Review Antiviral COVID-19 MK-4482 Lagevrio (U.S.) (May 2021) (1)(7) Cancer MK-1026 (nemtabrutinib) Hematological Malignancies (March 2023) MK-1308A (quavonlimab+pembrolizumab) Renal Cell (April 2021) MK-3475 Keytruda Biliary (September 2019) Cutaneous Squamous Cell (August 2019) (EU) Hepatocellular (May 2016) (EU) Mesothelioma (May 2018) Ovarian (December 2018) Small-Cell Lung (May 2017) MK-3475 (pembrolizumab subcutaneous) Non-Small-Cell Lung (August 2021) MK-3475A (pembrolizumab+hyaluronidase subcutaneous) Non-Small-Cell Lung (February 2023) MK-4280A (favezelimab+pembrolizumab) Colorectal (November 2021) Hematological Malignancies (October 2022) MK-6482 Welireg (3) Renal Cell (February 2020) MK-7119 Tukysa (1) Breast (October 2019) Colorectal (August 2022) MK-7339 Lynparza (1)(2) Non-Small-Cell Lung (June 2019) Small-Cell Lung (December 2020) MK-7684A (vibostolimab+pembrolizumab) Melanoma (January 2023) Non-Small-Cell Lung (April 2021) Small-Cell Lung (March 2022) MK-7902 Lenvima (1)(2) Esophageal (July 2021) Gastric (December 2020) Head and Neck (February 2020) Non-Small-Cell Lung (March 2019) HIV-1 Infection MK-8591A (doravirine+islatravir) (February 2020) (5) Pneumococcal Vaccine Adult V116 (July 2022) Pulmonary Arterial Hypertension MK-7962 (sotatercept) (January 2021) Respiratory Syncytial Virus MK-1654 (clesrovimab) (November 2021) New Molecular Entities Antiviral COVID-19 MK-4482 Lagevrio (EU) (1)(8) Cough MK-7264 (gefapixant) (U.S.) (9) (EU) Certain Supplemental Filings Cancer MK-3475 Keytruda \u2022    Second-Line Hepatocellular Carcinoma (KEYNOTE-394) (U.S.) \u2022    Locally Advanced or Metastatic Merkel Cell Carcinoma (KEYNOTE-913) (U.S.) \u2022    First-Line HER2 Negative Locally Advanced Unresectable or Metastatic Gastric Cancer (KEYNOTE-859) (U.S.) (EU) \u2022    Resectable Stage II, IIIA or IIIB NSCLC (KEYNOTE-671) (U.S.) (EU) \u2022    Adjuvant Non-Small-Cell Lung Cancer (KEYNOTE-091) (EU) \u2022    Relapsed or Refractory Primary Mediastinal B-Cell Lymphoma (KEYNOTE-170/KEYNOTE-A33) (JPN) MK-7339 Lynparza (1) \u2022    First-Line Metastatic Prostate Cancer (PROpel) (U.S.) (JPN) Footnotes: (1) Being developed in a collaboration.",
      "score": -0.9879
    },
    {
      "sent": "- 36 - Phase 2 Cancer MK-0482 (2) Non-Small-Cell Lung MK-1308 (quavonlimab) (2) Non-Small-Cell Lung MK-1308A (quavonlimab+pembrolizumab) Colorectal Hepatocellular Melanoma Small-Cell Lung MK-2140 (zilovertamab vedotin) Bladder Breast Gastric Hematological Malignancies Non-Small-Cell Lung Ovarian Pancreatic MK-2870 (1)(3) Neoplasm Malignant MK-3475 Keytruda Advanced Solid Tumors Prostate MK-3543 (bomedemstat) Myeloproliferative Disorders MK-4280 (favezelimab) (2) Non-Small-Cell Lung MK-4280A (favezelimab+pembrolizumab) Baldder Esophageal Melanoma Renal Cell Small-Cell Lung MK-4830 (2) Colorectal Esophageal Melanoma Non-Small-Cell Lung Ovarian Renal Cell Small-Cell Lung MK-5684 (1) Prostate MK-5890 (boserolimab) (2) Non-Small-Cell Lung Small-Cell Lung Cancer MK-6440 (ladiratuzumab vedotin) (1)(3) Breast Esophageal Gastric Head and Neck Melanoma Non-Small-Cell Lung Prostate Small-Cell Lung MK-6482 Welireg (3) Biliary Colorectal Endometrial Esophageal Hepatocellular Pancreatic Rare cancers Von Hippel-Lindau Disease-Associated Tumors (EU) MK-7119 Tukysa (1) Advanced Solid Tumors Biliary Bladder Cervical Endometrial Gastric Non-Small-Cell Lung MK-7339 Lynparza (1)(3) Advanced Solid Tumors MK-7684A (vibostolimab+pembrolizumab) Biliary Bladder Breast Cervical Colorectal Endometrial Esophageal Gastric Head and Neck Hematological Malignancies Hepatocellular Ovarian Prostate Cancer MK-7902 Lenvima (1)(2) Biliary Melanoma Pancreatic Prostate Small-Cell Lung V940 (1)(2) Melanoma Dengue Fever Virus Vaccine V181 HIV-1 Infection MK-8591B (islatravir+MK-8507) (4) MK-8591D (islatravir+lenacapavir) (1)(5) Hypercholesterolemia MK-0616 Nonalcoholic Steatohepatitis (NASH) MK-6024 (efinopegdutide) Pulmonary Arterial Hypertension MK-5475 Pulmonary Hypertension Due To Left Heart Disease MK-7962 (sotatercept) Schizophrenia MK-8189 (6) Thrombosis MK-2060 Treatment Resistant Depression MK-1942 - 37 - Phase 3 (Phase 3 entry date) Under Review Antiviral COVID-19 MK-4482 Lagevrio (U.S.) (May 2021) (1)(7) Cancer MK-1026 (nemtabrutinib) Hematological Malignancies (March 2023) MK-1308A (quavonlimab+pembrolizumab) Renal Cell (April 2021) MK-3475 Keytruda Biliary (September 2019) Cutaneous Squamous Cell (August 2019) (EU) Hepatocellular (May 2016) (EU) Mesothelioma (May 2018) Ovarian (December 2018) Small-Cell Lung (May 2017) MK-3475 (pembrolizumab subcutaneous) Non-Small-Cell Lung (August 2021) MK-3475A (pembrolizumab+hyaluronidase subcutaneous) Non-Small-Cell Lung (February 2023) MK-4280A (favezelimab+pembrolizumab) Colorectal (November 2021) Hematological Malignancies (October 2022) MK-6482 Welireg (3) Renal Cell (February 2020) MK-7119 Tukysa (1) Breast (October 2019) Colorectal (August 2022) MK-7339 Lynparza (1)(2) Non-Small-Cell Lung (June 2019) Small-Cell Lung (December 2020) MK-7684A (vibostolimab+pembrolizumab) Melanoma (January 2023) Non-Small-Cell Lung (April 2021) Small-Cell Lung (March 2022) MK-7902 Lenvima (1)(2) Esophageal (July 2021) Gastric (December 2020) Head and Neck (February 2020) Non-Small-Cell Lung (March 2019) HIV-1 Infection MK-8591A (doravirine+islatravir) (February 2020) (5) Pneumococcal Vaccine Adult V116 (July 2022) Pulmonary Arterial Hypertension MK-7962 (sotatercept) (January 2021) Respiratory Syncytial Virus MK-1654 (clesrovimab) (November 2021) New Molecular Entities Antiviral COVID-19 MK-4482 Lagevrio (EU) (1)(8) Cough MK-7264 (gefapixant) (U.S.) (9) (EU) Certain Supplemental Filings Cancer MK-3475 Keytruda \u2022    Second-Line Hepatocellular Carcinoma (KEYNOTE-394) (U.S.) \u2022    Locally Advanced or Metastatic Merkel Cell Carcinoma (KEYNOTE-913) (U.S.) \u2022    First-Line HER2 Negative Locally Advanced Unresectable or Metastatic Gastric Cancer (KEYNOTE-859) (U.S.) (EU) \u2022    Resectable Stage II, IIIA or IIIB NSCLC (KEYNOTE-671) (U.S.) (EU) \u2022    Adjuvant Non-Small-Cell Lung Cancer (KEYNOTE-091) (EU) \u2022    Relapsed or Refractory Primary Mediastinal B-Cell Lymphoma (KEYNOTE-170/KEYNOTE-A33) (JPN) MK-7339 Lynparza (1) \u2022    First-Line Metastatic Prostate Cancer (PROpel) (U.S.) (JPN) Footnotes: (1) Being developed in a collaboration.",
      "score": -0.9879
    },
    {
      "sent": "Keytruda is an anti-PD-1 (programmed death receptor-1) therapy that has been approved as monotherapy for the treatment of certain patients with cervical cancer, classical Hodgkin lymphoma, cutaneous squamous cell carcinoma, esophageal or gastroesophageal junction (GEJ) carcinoma, head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), non-small-cell lung cancer (NSCLC), melanoma, Merkel cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer (solid tumors) including MSI-H/dMMR colorectal cancer, MSI-H/dMMR advanced endometrial carcinoma, primary mediastinal large B-cell lymphoma (PMBCL), tumor mutational burden-high (TMB-H) cancer (solid tumors), and urothelial carcinoma including non-muscle invasive bladder cancer.",
      "score": -0.9834
    }
  ],
  "forward_snippets": [
    "Recently Adopted Accounting Standard In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance.",
    "The Company adopted the guidance effective January 1, 2023.",
    "The adoption of this guidance did not have an impact on the Company\u2019s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.",
    "Recently Issued Accounting Standard Not Yet Adopted In June 2022, the FASB issued guidance related to the fair value measurement of an equity security subject to contractual restrictions that prohibit the sale of the equity security.",
    "The new guidance also introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value."
  ]
}